Compare Repligen Corporation Common Stock (RGEN) vs Vanguard Dividend Appreciation Index Fund ETF (VIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Vanguard Dividend Appreciation Index Fund ETF trades at $239.98 (market cap $132.40B). The key difference: Vanguard Dividend Appreciation Index Fund ETF is far larger — about 11.9× Repligen Corporation Common Stock's market cap, and Repligen Corporation Common Stock is more actively traded (1,259,263 versus 1,027,126). Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Vanguard Dividend Appreciation Index Fund ETF for 134 Days on average.
| RGEN | VIG | |
|---|---|---|
Market Cap | $11.14B | $132.40B |
Volume | 1,259,263 | 1,027,126 |
Sector | Health | — |
52-Week High | $194.57 | $246.61 |
52-Week Low | $102.87 | $210.70 |
Typical Hold Time | 0 Days | 134 Days |
Enterprise Value | $11.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
VIG trades at $239.98, showing minimal daily movement with a slight decline of 0.02%. The technical outlook is bullish based on moving averages, though oscillators are neutral. Recent news highlights its focus on dividend growth, with a 7.5% quarterly dividend increase noted by Seeking Alpha on September 27, 2026. The ETF's strategy excludes high-yield stocks to prioritize consistent dividend growers, as reported by The Motley Fool on September 26, 2026.
The outlook for VIG is supported by its historical average annual returns of 10%, but risks include slow dividend growth and competition from higher-yield ETFs. Investor sentiment is mixed, with some analysts favoring its growth profile over immediate income. Key risks involve market volatility and the ETF's strict eligibility criteria limiting yield potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Vanguard Dividend Appreciation Index Fund ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →
